E-cigarettes—An unintended illicit drug delivery system

Drug and Alcohol Dependence

Volumn 192, Issue , 2018, Pages 98-111

  Breitbarth, Andreas K ^a   Morgan, Jody ^b   Jones, Alison L ^b  

^a Illawarra Shoalhaven Local Health District   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

E cigarettes; Electronic nicotine delivery systems; Recreational drugs; Toxicology; Vaping

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; ALPHA PYRROLIDINOPENTIOPHENONE; CANNABINOID; CANNABIS; CATHINONE; COCAINE; DIAMORPHINE; DRONABINOL; FENTANYL; FENTANYL DERIVATIVE; METHAMPHETAMINE; METHYLONE; MIDOMAFETAMINE; PENTEDRONE; UNCLASSIFIED DRUG; NICOTINE; STREET DRUG;

AGGRESSION; AGITATION; ANGINA PECTORIS; CLINICIAN; COMA; DENTAL CARIES; DIAPHORESIS; DRUG DELIVERY SYSTEM; DYSPNEA; HALLUCINATION; HEADACHE; HEALTH HAZARD; HEALTH SURVEY; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTHERMIA; INSOMNIA; KIDNEY FAILURE; MEDICAL LITERATURE; NAUSEA; ONLINE SYSTEM; PARANOIA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; SEIZURE; SUICIDAL IDEATION; THIRST; UNITED STATES; VAPING; VOMITING; ELECTRONIC CIGARETTE; EPIDEMIOLOGY; PROCEDURES; TOBACCO; TRENDS;

DRUG DELIVERY SYSTEMS; ELECTRONIC NICOTINE DELIVERY SYSTEMS; HUMANS; NICOTINE; STREET DRUGS; TOBACCO PRODUCTS; VAPING;

EID: 85053551559     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2018.07.031     Document Type: Review

References (198)

1. Abbott, R., Smith, D.E., The new designer drug wave: a clinical, toxicological, and legal analysis. J. Psychoact. Drugs 47 (2015), 368–371, 10.1080/02791072.2015.1094591.
2. Abrams, D.I., Vizoso, H.P., Shade, S.B., Jay, C., Kelly, M.E., Benowitz, N.L., Vaporization as a smokeless cannabis delivery system: a pilot study. Clin. Pharmacol. Ther. 82 (2007), 572–578, 10.1038/sj.clpt.6100200.
3. Adams, I.B., Martin, B.R., Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (1996), 1585–1614, 10.1046/j.1360-0443.1996.911115852.x.
4. Adkison, S.E., O'Connor, R.J., Bansal-Travers, M., Hyland, A., Borland, R., Yong, H.-H., Cummings, K.M., McNeill, A., Thrasher, J.F., Hammond, D., Electronic nicotine delivery systems: international tobacco control four-country survey. Am. J. Prev. Med. 44 (2013), 207–215, 10.1016/j.amepre.2012.10.018.
5. Australian Institute of Health and Welfare (AIHW), 2007 National Drug Strategy Household Survey: Detailed Findings. 2008 Accessed 4 January 2018 http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442459906.
6. Albertson, T.E., Opiates and opioids. Olson, K.R., (eds.) Poisoning and Drug Overdose, 2012, McGraw-Hill Education, USA.
7. Ambrose, B.K., Rostron, B.L., Johnson, S.E., Portnoy, D.B., Apelberg, B.J., Kaufman, A.R., Choiniere, C.J., Perceptions of the relative harm of cigarettes and e-cigarettes among U.S. youth. Am. J. Prev. Med. 47 (2014), 53–60, 10.1016/j.amepre.2014.04.016.
8. Anand, V., McGinty, K.L., O'Brien, K., Guenthner, G., Hahn, E., Martin, C.A., E-cigarette use and beliefs among urban public high school students in. North. Carol. J. Adolesc. Health 57 (2015), 46–51, 10.1016/j.jadohealth.2015.03.018.
9. Andonian, D.O., Seaman, S.R., Josephson, E.B., Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication – a case series. Am. J. Emerg. Med. 35:940 (2017), e945–940, 10.1016/j.ajem.2017.01.011 e946.
10. Anizan, S., Concheiro, M., Lehner, K.R., Bukhari, M.O., Suzuki, M., Rice, K.C., Baumann, M.H., Huestis, M.A., Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmcodynamic effects. Addict. Biol. 21 (2014), 339–347, 10.1111/adb.12201.
11. Araujo, A.M., Valente, M.J., Carvalho, M., Silva, D.Dd., Gaspar, H., Carvalho, F., Bastos, Md.L., Pinho, P.G.D., Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of ‘legal high’ packages containing synthetic cathinones. Arch. Toxicol. 89 (2015), 757–771, 10.1007/s00204-014-1278-7.
12. Armenian, P., Vo, K.T., Barr-Walker, J., Lynch, K.L., Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacol. 134:Pt A (2017), 121–132, 10.1016/j.neuropharm.2017.10.016.
13. Backberg, M., Lindeman, E., Beck, O., Helander, A., Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin. Toxicol. 53 (2015), 46–53, 10.3109/15563650.2014.981823.
14. Bahl, V., Lin, S., Xu, N., Davis, B., Wang, Y.-h., Talbot, P., Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod. Toxicol. 34 (2012), 529–537, 10.1016/j.reprotox.2012.08.001.
15. Barbeau, A.M., Burda, J., Siegel, M., Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict. Sci. Clin. Pract., 8, 2013, 5, 10.1186/1940-0640-8-5.
16. Barrios, L., Grison-Hernando, H., Boels, D., Bouquie, R., Monteil-Ganiere, C., Clement, R., Death following ingestion of methylone. Int. J. Leg. Med. 130 (2016), 381–385, 10.1007/s00414-015-1212-4.
17. Baselt, R.C., Disposition of Toxic Drugs and Chemicals in Man. 9th edition, 2011, Biomedical Publications, Seal Beach, CA.
18. Bell, D.S., The experimental reproduction of amphetamine psychosis. Arch. Gen. Psychiatry. 29 (1973), 35–40, 10.1001/archpsyc.1973.04200010020003.
19. Bell, S., Nida, C., Pyrolysis of drugs of abuse: a comprehensive review. Drug Test. Anal. 7 (2015), 445–456, 10.1002/dta.1794.
20. Benowitz, N.L., Marijuana. Olson, K., (eds.) Poisoning and Drug Overdose, 6th edition, 2012, McGraw-Hill Education, USA.
21. Benowitz, N.L., Cocaine. Olson, K., (eds.) Poisoning and Drug Overdose, 6th edition, 2012, McGraw-Hill Education, USA.
22. Besaratinia, A., Tommasi, S., An opportune and unique research to evalute the public health impact of electronic cigarettes. Cancer Causes Control 28 (2017), 1167–1171, 10.1007/s10552-017-0952-5.
23. Blundell, M., Dargan, P., Wood, D., A cloud on the horizon - a survey into the use of electronic vaping devices for recreational drug and new psychoactive substance (NPS) administration. QJM 111 (2018), 9–14, 10.1093/qjmed/hcx178.
24. Blundell, M.S., Dargan, P.I., Wood, D.M., The dark cloud of recreational drugs and vaping. QJM 111 (2018), 145–148, 10.1093/qjmed/hcx049.
25. Bonn-Miller, M.O., Loflin, M.E., Thomas, B.F., Marcu, J.P., Hyke, T., Vandrey, R., Labeling accuracy of cannabidiol extracts sold online. JAMA 318 (2017), 1708–1709, 10.1001/jama.2017.11909.
26. Borodovsky, J.T., Crosier, B.S., Lee, D.C., Sargent, J.D., Budney, A.J., Smoking, vaping, eating: Is legalization impacting the way people use cannabis?. Int. J. Drug Policy 36 (2016), 141–147, 10.1016/j.drugpo.2016.02.022.
27. Borodovsky, J.T., Lee, D.C., Crosier, B.S., Gabrielli, J.L., Sargent, J.D., Budney, A.J., U.S. cannabis legalization and use of vaping and edible products among youth. Drug. Alcohol. Depend. 177 (2017), 299–306, 10.1016/j.drugalcdep.2017.02.017.
28. Brownlow, H.A., Pappachan, J., Pathophysiology of cocaine abuse. Eur. J. Anaesthesiol. 19 (2002), 395–414, 10.1017/S0265021502000650.
29. Budney, A.J., Sargent, J.D., Lee, D.C., Vaping cannabis (marijuana): parallel concerns to e-cigs?. Addiction 110 (2015), 1699–1704, 10.1111/add.13036.
30. Bullen, C., Howe, C., Laugesen, M., McRobbie, H., Parag, V., Williman, J., Walker, N., Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382 (2013), 1629–1637, 10.1016/S0140-6736(13)61842-5.
31. Busardo, F.P., Kyriakou, C., Napoletano, S., Marinelli, E., Zaami, S., Mephedrone related fatalities: a review. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 3777–3790.
32. Cantrell, F., Adverse effects of e-cigarette exposures. J. Commun. Health 39 (2014), 614–616, 10.1007/s10900-013-9807-5.
33. Carlier, J., Scheidweiler, K.B., Wohlfarth, A., Salmeron, B.D., Baumann, M.H., Huestis, M.A., Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone(AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1451 (2016), 97–106, 10.1016/j.chroma.2016.05.020.
34. Carlini, B.H., Garrett, S.B., Harwick, R.M., Beyond joints and brownies: marijuana concentrates in the legal landscape of WA State. Int. J. Drug Policy 42 (2017), 26–29, 10.1016/j.drugpo.2017.01.004.
35. Castaneto, M.S., Gorelick, D.A., Desrosiers, N.A., Hartman, R.L., Pirard, S., Huestis, M.A., Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 144 (2014), 12–41, 10.1016/j.drugalcdep.2014.08.005.
36. Castaneto, M.S., Wohlfarth, A., Desrosiers, N.A., Hartman, R.L., Gorelick, D.A., Huestis, M.A., Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab. Rev., 2015, 1–51, 10.3109/03602532.2015.1029635.
37. Castellanos, D., Gralnik, L.M., Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J. Clin. Pediatr. 5 (2016), 16–24, 10.5409/wjcp.v5.i1.16.
38. Cavazos-Rehg, P.A., Sowles, S.J., Krauss, M.J., Agbonavbare, V., Grucza, R., Bierut, L., A content analysis of tweets about high-potency marijuana. Drug. Alcohol. Depend. 166 (2016), 100–108, 10.1016/j.drugalcdep.2016.06.034.
39. Cho, A.K., Ice: a new dosage form of an old drug. Science, 249, 1990, 631, 10.1126/science.249.4969.631.
40. Clarke, E.G.C., Moffat, A.C., Clarke's Isolation and Identification of Drugs in Pharmaceuticals. 2nd edition, 1986, The Pharmaceutical Press, London.
41. Cranford, J.A., Bohnert, K.M., Perron, B.E., Bourque, C., Prevalence and correlates of’ vaping’ as a route of cannabis administration in medical cannabis patients. Drug Alcohol Depend. 169 (2016), 41–47, 10.1016/j.drugalcdep.2016.10.008.
42. Cruickshank, C.C., Dyer, K.R., A review of the clinical pharmacology of methamphetamine. Addiction 104 (2009), 1085–1099, 10.1111/j.1360-0443.2009.02564.x.
43. Cuttler, C., Mischley, L.K., Sexton, M., Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannab. Res. 1 (2016), 166–175, 10.1089/can.2016.0010.
44. Czogala, J., Goniewicz, M.L., Fidelus, B., Zielinska-Danch, W., Travers, M.J., Sobczak, A., Secondhand exposure to vapors from electronic cigarettes. Nicotine Tob. Res. 16 (2014), 655–662, 10.1093/ntr/ntt203.
45. Daniulaityte, R., Nahhas, R.W., Wijeratne, S., Carlson, R.G., Lamy, F.R., Martins, S.S., Boyer, E.W., Smith, G.A., Sheth, A., “Time for dabs”: analyzing twitter data on marijuana concentrates across the U.S. Drug Alcohol Depend. 155 (2015), 307–311, 10.1016/j.drugalcdep.2015.07.1199.
46. Daniulaityte, R., Lamy, F.R., Barratt, M., Nahhas, R.W., Martins, S.S., Boyer, E.W., Sheth, A., Carlson, R.G., Characterizing marijuana concentrate users: a web-based survey. Drug Alcohol Depend. 178 (2017), 399–407, 10.1016/j.drugalcdep.2017.05.034.
47. Dart, R.C., Medical Toxicology. 2004, Lippincott Williams & Wilkins, Philadelphia, PA.
48. Dawkins, L., Kimber, C., Puwanesarasa, Y., Soar, K., First‐versus second‐generation electronic cigarettes: predictors of choice and effects on urge to smoke and withdrawal symptoms. Addiction 110 (2015), 669–677, 10.1111/add.12807.
49. De La Torre, R., Farré M., Roset, P.N., Pizarro, N., Abanades, S., Segura, M., Segura, J., Camí J., Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26 (2004), 137–144.
50. Drug Enforcement Administration (DEA), 2016 National Drug Threat Assesment Summary. 2016 Accessed 23 November 2017 https://www.hsdl.org/?abstract&did=797265.
51. DeBruyne, D., Boisselier, R.L., Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst. Abuse Rehabil. 6 (2015), 113–129, 10.2147/SAR.S73586.
52. De-Carolis, C., Boyd, G.-A., Mancinelli, L., Pagano, S., Eramo, S., Methamphetamine abuse and “meth mouth” in Europe. Med. Oral Patol. Oral Cir. Bucal., 20, 2015, e205, 10.4317/medoral.20204.
53. Derungs, A., Schwaninger, A.E., Mansella, G., Bingisser, R., Kraemer, T., Liechti, M.E., Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 31 (2013), 164–171, 10.1007/s11419-012-0166-1.
54. Docherty, J.R., Pharmacology of stimulants prohibited by the world anti‐doping agency (WADA). Br. J. Pharmacol. 154 (2008), 606–622, 10.1038/bjp.2008.124.
55. Douglas, H., Hall, W., Gartner, C., E-cigarettes and the law in Australia. Aust. Fam. Physician. 44 (2015), 415–418.
56. Dresen, S., Kneisel, S., Weinmann, W., Zimmermann, R., Auwärter, V., Development and validation of a liquid chromatography–tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J. Mass. Spectrom. 46 (2011), 163–171, 10.1002/jms.1877.
57. DrugAbuse.com, Lautieri, A., (eds.) The Effetcs of Fentanyl Use, 2018 Accessed 13 April 2018 https://drugabuse.com/library/the-effects-of-fentanyl-use/.
58. Durmowicz, E.L., The impact of electronic cigarettes on the paediatric population. Tob. Control. 23 (2014), ii41–ii46, 10.1136/tobaccocontrol-2013-051468.
59. Dutra, L.M., Glantz, S.A., Electronic cigarettes and conventional cigarette use among US adolescents: a cross-sectional study. JAMA Pediatr. 168 (2014), 610–617, 10.1001/jamapediatrics.2013.5488.
60. Eggers, M.E., Lee, Y.O., Jackson, K., Wiley, J.L., Porter, L., Nonnomaker, J.M., Youth use of electronic vapor products and blunts for administering cannabis. Addict. Behav. 70 (2017), 79–82, 10.1016/j.addbeh.2017.02.020.
61. Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., Tiihonen, J., Pharmacotherapy of methamphetamine addiction: an update. Subst. Abuse. 29 (2008), 31–49, 10.1080/08897070802218554.
62. Ellefsen, K.N., Concheiro, M., Huestis, M.A., Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metab. Rev. 48 (2016), 237–265, 10.1080/03602532.2016.1188937.
63. Ellenhorn, M.J., Schonwald, S., Ordog, G., Wasserberger, J., Ellenhorn'S Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd edition, 1997, Williams & Wilkins, Baltimore, MD.
64. ElSohly, M.A., Gul, W., Wanas, A.S., Radwan, M.M., Synthetic cannabinoids: analysis and metabolites. Life Sci. 97 (2014), 78–90, 10.1016/j.lfs.2013.12.212.
65. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Cocaine and Crack Drug Profile. 2015 Accessed 2 September 2015 http://www.emcdda.europa.eu/publications/drug-profiles/cocaine.
66. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Heroin Drug Profile. 2015 Accessed 2 September 2015 http://www.emcdda.europa.eu/publications/drug-profiles/heroin.
67. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Methylenedioxymethamphetamine (MDMA or’ Ecstasy’) Drug Profile. 2015 Accessed 2 September 2015 http://www.emcdda.europa.eu/publications/drug-profiles/mdma.
68. Etter, J.F., Electronic cigarettes and cannabis: an exploratory study. Eur. Addict. Res. 21 (2015), 124–130, 10.1159/000369791.
69. Eyupoglu, D., Ortac Ersoy, E., Rollas, K., Topeli, A., Acute eosinophilic pneumonia secondary to heroin inhalation. Tuberk Toraks 65 (2017), 154–156, 10.5578/tt.10438.
70. Farsalinos, K.E., Polosa, R., Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther. Adv. Drug Saf. 5 (2014), 67–86, 10.1177/2042098614524430.
71. Farsalinos, K.E., Kistler, K.A., Gillman, G., Voudris, V., Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob. Res. 17 (2015), 168–174, 10.1093/ntr/ntu176.
72. Favrod-Coune, T., Broers, B., The health effect of psychostimulants: a literature review. Pharmaceuticals 3 (2010), 2333–2361, 10.3390/ph3072333.
73. Froberg, B.A., Levine, M., Beuhler, M.C., Judge, B.S., Moore, P.W., Engebretsen, K.M., Mckeown, N.J., Rosenbaum, C.D., Young, A.C., Rusyniak, D.E., Acute methylenedioxypyrovalerone toxicity. J. Med. Toxicol. 11 (2015), 185–194, 10.1007/s13181-014-0446-8.
74. Frohe, T., Leeman, R.F., Patock-Peckham, J., Ecker, A., Kraus, S., Foster, D.W., Correlates of cannabis vape-pen use and knowledge among U.S. College students. Addict. Behav. Rep. 7 (2018), 32–39, 10.1016/j.abrep.2017.11.004.
75. Galli, J.A., Sawaya, R.A., Friedenberg, F.K., Cannabinoid hyperemesis syndrome. Curr. Drug Abuse Rev. 4 (2011), 241–249.
76. Garcia, R.C.T., Dati, L.M.M., Fukuda, S., Torres, L.H.L., Moura, S., de Carvalho, N.D., Carrettiero, D.C., Camarini, R., Levada-Pires, A.C., Yonamine, M., Negrini-Neto, O., Abdalla, F.M.F., Sandoval, M.R.L., Afeche, S.C., Marcourakis, T., Neurotoxicity of anhydroecgonine methyl ester, a crack cocaine pyrolysis product. Toxicol. Sci. 128 (2012), 223–234, 10.1093/toxsci/kfs140.
77. Gartner, C., Mull it over: Cannabis vaporizers and harm reduction. Addiction 110 (2015), 1709–1710, 10.1111/add.13139.
78. Gieringer, D.H., Cannabis “vaporization” a promising strategy for smoke harm reduction. J. Cannabis Ther. 1 (2001), 153–170, 10.1300/J175v01n03_10.
79. Gieringer, D., St, Laurent, J., Goodrich, S., Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J. Cannabis Ther. 4 (2004), 7–27, 10.1300/J175v04n01_02.
80. Giroud, C., de Cesare, M., Berthet, A., Varlet, V., Concha-Lozano, N., Favrat, B., E-cigarettes: a review of new trends in cannabis use. Int. J. Environ. Res. Publ. Health. 12 (2015), 9988–10008, 10.3390/ijerph120809988.
81. Glennon, R.A., Dukat, M., Structure-activity relationships of synthetic cathinones. Baumann, M.H., Glennon, R.A., Wiley, J.L., (eds.) Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 2017, Springer International Publishing, 19–48.
82. Glover, C., 6 Teens Hospitalized so Far from’ Cloud 9’ Drug. 2014 Accessed 28 September 2017 https://www.clickondetroit.com/news/6-teens-hospitalized-so-far-from-cloud-9-drug.
83. Goniewicz, M.L., Kuma, T., Gawron, M., Knysak, J., Kosmider, L., Nicotine levels in electronic cigarettes. Nicotine Tob. Res. 15 (2013), 158–166, 10.1093/ntr/nts103.
84. Goniewicz, M.L., Knysak, J., Gawron, M., Kosmider, L., Sobczak, A., Kurek, J., Prokopowicz, A., Jablonska-Czapla, M., Rosik-Dulewska, C., Havel, C., Levels of selected carcinogens and toxicants in vapor from electronic cigarettes. Tob. Control 23 (2014), 133–139, 10.1136/tobaccocontrol-2012-050859.
85. Goniewicz, M.L., Zielinska-Danch, W., Electronic cigarette use among teenagers and young adults in Poland. Pediatrics 130 (2012), 879–885, 10.1542/peds.2011-3448.
86. Gowing, L.R., Ali, R.L., Allsop, S., Marsden, J., Turf, E.E., West, R., Witton, J., Global statistics on addictive behaviours: 2014 status report. Addiction 110 (2015), 904–919, 10.1111/add.12899.
87. Green, A.R., King, M.V., Shortall, S.E., Fone, K.C.F., Lost in translation: preclinical studies on 3, 4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br. J. Pharmacol. 166 (2012), 1523–1536, 10.1111/j.1476-5381.2011.01819.x.
88. Greydanus, D., Kaplan, G., Baxter, L.E. Sr, Patel, D., Feucht, C., Cannabis: the never-ending, nefarious nepenthe of the 21st century: what should the clinician know?. Dis. Mon. 61 (2015), 118–175, 10.1016/j.disamonth.2015.01.004.
89. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42 (2003), 327–360, 10.2165/00003088-200342040-00003.
90. Hahn, I., Pritchard Taylor, J., (eds.) MDMA Toxicity, 2017 New York, NY https://emedicine.medscape.com/article/821572-overview#showall Accessed 19 April 2018.
91. Hakkarainen, P., Vaporizing the Pot World - Easy, Healthy, and Cool, vol. 16, 2016, 185–193.
92. Hall, W., The health and psychological effects of cannabis use. Curr. Issues Crim. Just. 6 (1994), 208–220, 10.1108/DAT-10-2015-0062.
93. Hartman, R.L., Brown, T.L., Milavetz, G., Spurgin, A., Gorelick, D.A., Gaffney, G., Huestis, M.A., Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin. Chem. 61 (2015), 850–869, 10.1373/clinchem.2015.238287.
94. Hatsukami, D.K., Fischman, M.W., Crack cocaine and cocaine hydrochloride: are the differences myth or reality?. JAMA 276 (1996), 1580–1588, 10.1001/jama.1996.03540190052029.
95. He, T., Oks, M., Esposito, M., Steinberg, H., Makaryus, M., ’Tree-in-bloom’: severe acute lung injury induced by vaping cannabis oil. Ann. Am. Thorac. Soc. 13 (2017), 468–470, 10.1513/AnnalsATS.201612-974LE.
96. Heard, K., Palmer, R., Zahniser, N.R., Mechanisms of acute cocaine toxicity. Open Pharmacol. J., 2, 2008, 70, 10.2174/1874143600802010070.
97. Hedegaard, H., Warner, M., Miniño, A., Drug overdose deaths in the United States, 1999-2016. NCHS Data Brief, No 294, 2017, National Center for Health Statistics, Hyattsville, MD 2017.
98. Heikkila, R.E., Orlansky, H., Cohen, G., Studies on the distinction between uptake inhibition and release of [3 H] dopamine in rat brain tissue slices. Biochem. Pharmacol. 24 (1975), 847–852, 10.1016/0006-2952(75)90152-5.
99. Hermanns-Clausen, M., Kneisel, S., Szabo, B., Auwärter, V., Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108 (2013), 534–544, 10.1111/j.1360-0443.2012.04078.x.
100. Hindocha, C., Freeman, T.P., Ferris, J.A., Lynskey, M.T., Winstock, A.R., No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front. Psychiatry, 7, 2016, 104, 10.3389/fpsyt.2016.00104.
101. Hoch, E., Bonnet, U., Thomasius, R., Ganzer, F., Havemann-Reinecke, U., Preuss, U.W., Risks associated with the non-medicinal use of cannabis. Dtsch. Arztebl. Int., 112, 2015, 271, 10.3238/arztebl.2015.0271.
102. Howell, L.L., Kimmel, H.L., Monoamine transporters and psychostimulant addiction. Biochem. Pharmacol. 75 (2008), 196–217, 10.1016/j.bcp.2007.08.003.
103. Johnson, R.M., Brooks-Russell, A., Ma, M., Fairman, B.J., Tolliver, R.L., Levinson, A.H., Usual modes of marijuana consumption among high school students in Colorado. J. Stud. Alcohol. Drugs. 77 (2016), 580–588, 10.15288/jsad.2016.77.580.
104. Jones, C.B., Hill, M.L., Pardini, D.A., Meier, M.H., Prevalence and correlates of vaping cannabis in a sample of young adults. Psych. Adict. Behav. 30 (2016), 915–921, 10.1037/adb0000217.
105. Kandel, D., Kandel, E., The gateway hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatrica. 104 (2015), 130–137, 10.1111/apa.12851.
106. Karila, L., Megarbane, B., Cottencin, O., Lejoyeux, M., Synthetic cathinones: a new public health problem. Curr. Neuropharmacol. 13 (2015), 12–20, 10.2174/1570159X13666141210224137.
107. Kenne, D.R., Fischbein, R.L., Tan, A.S., Banks, M., The use of substances other than nicotine in electronic cigarettes among college students. J. Subst. Abuse Treat. 11 (2017), 1–8, 10.1177/1178221817733736.
108. Kersten, B.P., McLaughlin, M.E., Toxicology and management of novel psychoactive drugs. J. Pharm. Pract. 28 (2015), 50–65, 10.1177/0897190014544814.
109. Khlystov, A., Samburova, V., Flavoring compounds dominate toxic aldehyde production during e-cigarette vaping. Environ. Sci. Technol. 50 (2016), 13080–13085, 10.1021/acs.est.6b05145.
110. Kim, J.-H., Kwon, S.-S., Kong, T.Y., Cheong, J.C., Kim, H.S., In, M.K., Lee, H.S., AM-2201 inhibits multiple cytochrome P450 and uridine 50-diphospho-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules, 22, 2017, E443, 10.3390/molecules22030443.
111. Kish, S.J., Pharmacologic mechanisms of crystal meth. CMAJ. 178 (2008), 1679–1682, 10.1503/cmaj.071675.
112. Koller, V.J., Zlabinger, G.J., Auwärter, V., Fuchs, S., Knasmueller, S., Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1. Arch. Toxicol. 87 (2013), 1287–1297, 10.1007/s00204-013-1029-1.
113. Krauss, M.J., Sowles, S.J., Mvylaganam, S., Zewdie, K., Beirut, L.J., Cavazos-Rehg, P.A., Displays of dabbing marijuana extracts on YouTube. Drug. Alcohol. Depend. 155 (2015), 45–51, 10.1016/j.drugalcdep.2015.08.020.
114. Kumar, K., Morgan, D.J., Crankshaw, D.P., Determination of fentanyl and alfentanil in plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 419 (1987), 464–468, 10.1016/0378-4347(87)80317-1.
115. Lacy, Ed., Fletcher, A., Hewitt, G., Murphy, S., Moore, G., Cross-sectional study examining the prevalence, correlates and sequencing of electronic cigarette and tobacco use among 11-16-year olds in schools in Wales. BMJ Open, 6, 2017, e012784, 10.1136/bmjopen-2016-012784.
116. Lake, C.R., Quirk, R.S., CNS stimulants and the look-alike drugs. Psychiatr. Clin. North. Am. 7 (1984), 689–701.
117. Lam, R., Tang, M., Leung, S., Chong, Y., Tsui, M., Mak, T., Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative anaylsis of serum drug concentrations. Clin. Toxicol. 55 (2017), 662–667, 10.1080/15563650.2017.1307385.
118. Lankenau, S.E., Fedorova, E.V., Reed, M., Schrager, S.M., Iverson, E., Wong, C.F., Marijuana practices and patterns of use among young adult medical marijuana patients and non-patient users. Drug. Alcohol. Depend. 170 (2017), 181–188, 10.1016/j.drugalcdep.2016.10.025.
119. Lanz, C., Mattsson, J., Soydaner, U., Brenneisen, R., Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PLoS One, 11, 2016, e0147286, 10.1371/journal.pone.0147286.
120. Lappin, J.M., Darke, S., Farrell, M., Stroke and methamphetamine use in young adults: a review. J. Neurol. Neurosurg. Psychiatry 88 (2017), 1079–1091, 10.1136/jnnp-2017-316071.
121. Lee, D.C., Crosier, B.S., Borodovsky, J.T., Sargent, J.D., Budney, A.J., Online survey characterizing vaporizer use among cannabis users. Drug Alcohol. Depend. 159 (2016), 227–233, 10.1016/j.drugalcdep.2015.12.020.
122. Leikin, J.B., Paloucek, F.P., Poisoning and Toxicology Handbook. 2007, Taylor & Francis, U.S.
123. Leventhal, A.M., Strong, D.R., Kirkpatrick, M.G., Unger, J.B., Sussman, S., Riggs, N.R., Stone, M.D., Khoddam, R., Samet, J.M., Audrain-McGovern, J., Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA 314 (2015), 700–707, 10.1001/jama.2015.8950.
124. Loflin, M., Earleywine, M., The case for medical marijuana: an issue of relief. Drug. Alcohol Depend. 149 (2015), 293–297, 10.1016/j.drugalcdep.2015.01.006.
125. Luethi, D., Kolaczynska, K.E., Docci, L., Krahenbuhl, S., Hoener, M.C., Liechti, M.E., Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacol 134:Pt A (2017), 4–12, 10.1016/j.neuropharm.2017.07.026.
126. Magnano, A.R., Talathoti, N.B., Hallur, R., Jurus, D.T., Dizon, J., Holleran, S., Bloomfield, D.M., Collins, E., Garan, H., Effect of acute cocaine administration on the QTc interval of habitual users. Am. J. Cardiol. 97 (2006), 1244–1246, 10.1016/j.amjcard.2005.11.046.
127. Mammen, G., Rehm, J., Rueda, S., Vaporizing cannabis through e-cigarettes: prevalence and socio-demographic correlates among Ontario high school students. Can. J. Public Health., 107, 2016, e337, 10.17269/CJPH.107.5747.
128. Martin, T.L., Woodall, K.L., McLellan, B.A., Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002–2004). J. Anal. Toxicol. 30 (2006), 603–610, 10.1093/jat/30.8.603.
129. Marusich, J.A., Lefever, T.W., Blough, B.E., Thomas, B.F., Wiley, J.L., Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology 55 (2016), 83–91, 10.1016/j.neuro.2016.05.015.
130. Matsunaga, T., Morikawa, Y., Kamata, K., Shibata, A., Miyazono, H., Sasajima, Y., Suenami, K., Sato, K., Takekoshi, Y., Endo, S., El-Kabbani, O., Ikari, A., α-pyrrolidinononanophenone provokes apoptosis of neuronal cells through alterations in antioxidant properties. Toxicology 386 (2017), 93–102, 10.1016/j.tox.2017.05.017.
131. McAuley, T.R., Hopke, P.K., Zhao, J., Babaian, S., Comparison of the effects of e-cigarette vapor and cigarette smoke on indoor air quality. Inhal. Toxicol. 24 (2012), 850–857, 10.3109/08958378.2012.724728.
132. McCloskey, K., Vearrier, D., McKeever, R.G., Greenberg, M., E-cigarettes and synthetic cannabinoids: a new trend. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) Vol. 55 (2016), 344–519.
133. McDonald, E.A., Popova, L., Ling, P.M., Traversing the triangulum: the intersection of tobacco, legalised marijuana and electronic vaporizers in Denver, Colorado. Tob. Control. 25 (2016), i96–i102, 10.1136/tobaccocontrol-2016-053091.
134. McGuigon, M., Cannabinoids. Flomenbaum, N.E., Goldfrank, L.R., Hoffman, R., Howland, M.A., Lewin, N.A., Nelson, L., (eds.) Goldfrank's Toxicological Emergencies, 8th ed, 2006, McGraw-Hill, New York, 1212–1220.
135. McNeill, B., Researchers Study the Use of E-Cigarettes for Illicit Drugs. 2016 Accessed 13 December 2017 https://medicalxpress.com/news/2016-06-e-cigarettes-illicit-drugs.html.
136. Mehta, J.J., Mahendran, A.K., Bajaj, R.K., Doshi, A.R., Myocardial ischemia with cannabinoid use in an adolescent. Cureus, 9, 2017, e1899, 10.7759/cureus.1899.
137. Mills, B., Yepes, A., Nugent, K., Synthetic cannabinoids. Am. J. Med. Sci. 350 (2015), 59–62, 10.1097/MAJ.0000000000000466.
138. Morean, M.E., Kong, G., Camenga, D.R., Cavallo, D.A., Krishnan-Sarin, S., High school students’ use of electronic cigarettes to vaporize cannabis. Pediatrics 136 (2015), 611–616, 10.1542/peds.2015-1727.
139. Morean, M.E., Lipshie, N., Josephson, M., Foster, D., Predictors of adult e-cigarette users vaporizing cannabis using e-ciragettes and vape-pens. Subst. Use Misuse 52 (2017), 974–981, 10.1080/10826084.2016.1268162.
140. Müller, H., Sperling, W., Köhrmann, M., Huttner, H.B., Kornhuber, J., Maler, J.-M., The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 118 (2010), 309–310, 10.1016/j.schres.2009.12.001.
141. National Drug Early Warning System, National Drug Early Warning System (NDEWS) Sentinel Community Site Profile 2015: Atlanta Metro. 2015 Accessed 23 November 2017 https://ndews.umd.edu/sites/ndews.umd.edu/files/SCS%20Atlanta%20Metro%202015%20Final%20Web.pdf.
142. Nelson, L., Schwaner, R., Transdermal fentanyl: pharmacology and toxicology. J. Med. Toxicol., 5, 2009, 230, 10.1007/BF03178274.
143. Orr, K.K., Asal, N.J., Efficacy of electronic cigarettes for smoking cessation. Ann. Pharmacother. 48 (2014), 1502–1506, 10.1177/1060028014547076.
144. Pant, S., Deshmukh, A., Dholaria, B., Kaur, V., Ramavaram, S., Ukor, M., Teran, G.A., Spicy seizure. Am. J. Med. Sci. 344 (2012), 67–68, 10.1097/MAJ.0b013e31824cf5c2.
145. Papaseit, E., Molto, J., Muga, R., Torrens, M., Torre, Rd.l, Farre, M., Clinical pharmacology of the synthetic cathinone mephedrone. Baumann, M.H., Glennon, R.A., Wiley, J.L., (eds.) Neuropharmacology of New Psychoactive Substances (NPS) : The Science Behind the Headlines, 2017, Springer International Publishing, 313–332.
146. Patel, N., Ford, L., Jones, R., Bradberry, S.M., Vale, J.A., Poisoning to α-pyrrolidinovalerophenone (α-PVP), a synthetic cathinone. Clin. Toxicol. 55 (2017), 159–160, 10.1080/15563650.2016.1248291.
147. Peace, M.R., Butler, K.E., Wolf, C.E., Poklis, J.L., Poklis, A., Evaluation of two commercially available cannabidiol formulations for use in electronic cigarettes. Front. Pharmacol., 7, 2016, 279, 10.3389/fphar.2016.00279.
148. Peace, M.R., Stone, J.W., Poklis, J.L., Turner, J.B.M., Poklis, A., Analysis of a commercial marijuana e-cigarette formulation. J. Anal. Toxicol. 40 (2016), 374–378, 10.1093/jat/bkw021.
149. Peglow, S., Buchner, J., Briscoe, G., Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am. J. Addict. 21 (2012), 287–288, 10.1111/j.1521-0391.2012.00222.x.
150. Pellegrino, R.M., Tinghino, B., Mangiaracina, G., Marani, A., Vitali, M., Protano, C., Osborn, J.F., Cattaruzza, M.S., Electronic cigarettes: an evaluation of exposure to chemicals and fine particulate matter (PM). Ann. Ig. 24 (2012), 279–288.
151. Pillay, V.V., Modern Medical Toxicology. 2013, Jaypee Brothers, New Delhi.
152. Pisinger, C., Døssing, M., A systematic review of health effects of electronic cigarettes. Prev. Med. 69 (2014), 248–260, 10.1016/j.ypmed.2014.10.009.
153. Poklis, J.L., Mulder, H.A., Halquist, M.S., Wolf, C.E., Poklis, A., Peace, M.R., The blue lotus flower (nymphea caerulea) resin used in a new type of electronic cigarette, the re-buildable dripping atomizer. J. Psychoact. Drugs 49 (2017), 175–181, 10.1080/02791072.2017.1290304.
154. Raber, J.C., Elizinga, S., Kaplan, C., Understanding dabs: contamination concerns of cannabis concentrates and cannabinoids transfer during the act of dabbing. J. Toxicol. Sci. 40 (2015), 797–803, 10.2131/jts.40.797.
155. Rogers, J.S., Rehrer, S.J., Hoot, N.R., Acetylfentanyl: an emerging drug of abuse. J. Emerg. Med. 50 (2016), 433–436, 10.1016/j.jemermed.2015.10.014.
156. Rojkiewicz, M., Majchrzak, M., Celinski, R., Kus, P., Sajewicz, M., Identification and physicochemical characterization of 4-fluorobutyrfentanyl (1-((4-fluorophenyl)(1-phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF) in seized materials and post-mortem biological samples. Drug Test. Anal. 9 (2017), 405–414, 10.1002/dta.2135.
157. Rom, O., Pecorelli, A., Valacchi, G., Reznick, A.Z., Are e‐cigarettes a safe and good alternative to cigarette smoking?. Ann. N. Y. Acad. Sci. 1340 (2015), 65–74, 10.1111/nyas.12609.
158. Rook, E.J., Van Ree, J.M., Van Den Brink, W., Hillebrand, M.J., Huitema, A.D.R., Hendriks, V.M., Beijnen, J.H., Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid‐dependent patients. Basic. Clin. Pharmacol. Toxicol. 98 (2006), 86–96, 10.1111/j.1742-7843.2006.pto_233.x.
159. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001), 32–41, 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
160. Salani, D.A., Zdanowicz, M.M., Synthetic cannabinoids: the dangers of spicing it up. J. Psychosoc. Nurs. Ment. Health Serv. 53 (2015), 36–43, 10.3928/02793695-20150422-01.
161. Schauer, G.L., King, B.A., Bunnell, R.E., Promoff, G., McAfee, T.A., Toking, vaping, and eating for health or fun: marijuana use patterns in adults, US, 2014. Am. J. Prev. Med. 50 (2016), 1–8, 10.1016/j.amepre.2015.05.027.
162. Schifano, F., A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 173 (2004), 242–248, 10.1007/s00213-003-1730-5.
163. Schifano, F., Orsolini, L., Papanti, D., Corkery, J., NPS: medical consequences associated with their intake. Baumann, M.H., Glennon, R.A., Wiley, J.L., (eds.) Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 2017, Springer International Publishing, 351–380.
164. Schober, W., Szendrei, K., Matzen, W., Osiander-Fuchs, H., Heitmann, D., Schettgen, T., Jörres, R.A., Fromme, H., Use of electronic cigarettes (e-cigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers. Int. J. Hyg. Environ. Health. 217 (2014), 628–637, 10.1016/j.ijheh.2013.11.003.
165. Schraufnagel, D.E., Blasi, F., Drummond, M.B., Lam, D.C., Latif, E., Rosen, M.J., Sansores, R., Van Zyl-Smit, R., Electronic cigarettes. A position statement of the forum of international respiratory societies. Am. J. Respir. Crit. Care Med. 190 (2014), 611–618, 10.1164/rccm.201407-1198PP.
166. Schripp, T., Markewitz, D., Uhde, E., Salthammer, T., Does e‐cigarette consumption cause passive vaping?. Indoor Air. 23 (2013), 25–31, 10.1111/j.1600-0668.2012.00792.x.
167. Schroeder, M.J., Hoffman, A.C., Electronic cigarettes and nicotine clinical pharmacology. Tob. Control. 23 (2014), ii30–ii35, 10.1136/tobaccocontrol-2013-051469.
168. Selley, D.E., Cao, C.-C., Sexton, T., Schwegel, J.A., Martin, T.J., Childers, S.R., μ opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem. Pharmacol. 62 (2001), 447–455.
169. Shiplo, S., Asbridge, M., Leatherdale, S.T., Hammond, D., Medical cannabis use in Canada: vaporization and modes of delivery. Harm Reduct. J., 13, 2016, 10.1186/s12954-016-0119-9.
170. Sitte, H.H., Freissmuth, M., The reverse operation of Na+/Cl−‐coupled neurotransmitter transporters–why amphetamines take two to tango. J. Neurochem. 112 (2010), 340–355, 10.1111/j.1471-4159.2009.06474.x.
171. Smith, M.T., Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3‐glucuronide metabolites. Clin. Exp. Pharmacol. Physiol. 27 (2000), 524–528.
172. Solis, E., Electrophysiological actions of synthetic cathinones on monoamine transporters. Baumann, M.H., Glennon, R.A., Wiley, J.L., (eds.) Neuropharmacology of New Psychoactive Substances (NPS) : The Science Behind the Headlines, 2017, Springer International Publishing, 73–92.
173. Solowij, N., Grenyer, B.F., Grotenhermen, F., Russo, E., Long Term Effects of Cannabis on Psyche and Cognition. 2001, 299–311.
174. Steinkellner, T., Freissmuth, M., Sitte, H.H., Montgomery, T., The ugly side of amphetamines: short-and long-term toxicity of 3, 4-methylenedioxymethamphetamine (MDMA,‘Ecstasy’), methamphetamine and D-amphetamine. Biol. Chem. 392 (2011), 103–115, 10.1515/BC.2011.016.
175. Suzuki, J., El-Haddad, S., A review: fentanyl and non-pharmaceutical fentanyls. Drug. Alcohol. Depend. 171 (2017), 107–116, 10.1016/j.drugalcdep.2016.11.033.
176. Swortwood, M.J., Newmeyer, M.N., Andersson, M., Abulseoud, O.A., Scheidweiler, K.B., Huestis, M.A., Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug. Test. Anal. 9 (2016), 905–915, 10.1002/dta.2092.
177. Tai, S., Fantegrossi, W.E., Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. Baumann, M.H., Glennon, R.A., Wiley, J.L., (eds.) Neuropharmacology of New Psychoactive Substances (NPS) : The Science Behind the Headlines, 2017, Springer International Publishing, 249–262.
178. Thompson, G.R., Rosenkrantz, H., Schaeppi, U.H., Braude, M.C., Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol. Appl. Pharmacol. 25 (1973), 363–372.
179. Thurtle, N., Abouchedid, R., Archer, J.R.H., Ho, J., Yamamoto, T., Dargan, P.I., Wood, D.M., Prevalence of use of electronic nicotine delivery systems (ENDS) to vape recreational drugs by club patrons in South London. J. Med. Toxicol. 13 (2017), 61–65, 10.1007/s13181-016-0583-3.
180. Tisdale, J.E., Shimoyama, H., Sabbah, H.N., Webb, C.R., The effect of cocaine on ventricular fibrillation threshold in the normal canine heart. Pharmacotherapy 16 (1996), 429–437.
181. Trecki, J., Gerona, R.R., Schwartz, M.D., Synthetic cannabinoid-related illnesses and deaths. New Engl. J. Med. 373 (2015), 103–107, 10.1056/NEJMp1505328.
182. Troutt, W.D., DiDonato, M.D., Carbonyl compounds produced by vaporizing cannabis oil thinning agents. J. Altern. Complement. Med., 2017, 10.1089/acm.2016.0337.
183. Turner, A.R., Agrawal, S., Marijuana. StatPearls [Internet], 2017, StatPearls Publishing, Treasure Island (FL) 2018 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430801/.
184. Umebachi, R., Aoki, H., Sugita, M., Taira, T., Wakai, S., Saito, T., Inokuchi, S., Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. Clin. Toxicol. 54 (2016), 563–567, 10.3109/15563650.2016.1166508.
185. Vakkalanka, J.P., Hardison, L.S., Holstege, C.P., Epidemiological trends in electronic cigarette exposures reported to U.S. Poison centers. Clin. Toxicol. 52 (2014), 542–548, 10.3109/15563650.2014.913176.
186. Valsalan, R., Varghese, B., Soman, D., Buckmaster, J., Yew, S., Cooper, D., Multi-organ dysfunction due to bath salts: are we aware of this entity?. Intern. Med. 47 (2017), 109–111, 10.1111/imj.13307.
187. Van Dam, N.T., Earleywine, M., Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int. J. Drug. Policy. 21 (2010), 511–513, 10.1016/j.drugpo.2010.04.001.
188. Vandrey, R., Dunn, K.E., Fry, J.A., Girling, E.R., A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol. Depend. 120 (2012), 238–241, 10.1016/j.drugalcdep.2011.07.011.
189. Weaver, M.F., Hopper, J.A., Gunderson, E.W., Designer drugs 2015: assessment and management. Addict. Sci. Clin. Pract., 10, 2015, 10.1186/s13722-015-0024-7.
190. Weinstein, A.M., Rosca, P., Fattore, L., London, E.D., Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front. Psychiatry, 8, 2017, 156, 10.3389/fpsyt.2017.00156.
191. Werley, M.S., McDonald, P., Lilly, P., Kirkpatrick, D., Wallery, J., Byron, P., Venitz, J., Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in sprague-Dawley rats and beagle dogs. Toxicology 287 (2011), 76–90, 10.1016/j.tox.2011.05.015.
192. World Health Organisation (WHO) International Agency for Research on Cancer (IARC), Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines, vol. 89, 2007 Accessed 4 January 2018 http://monographs.iarc.fr/ENG/recentpub/mono89.pdf.
193. World Health Organisation (WHO) Framework Convention on Tobacco Control, Electronic Nicotine Delivery Systems. 2014 Accessed 4 January 2018 http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10Rev1-en.pdf?ua=1.
194. Williams, M., Villarreal, A., Bozhilov, K., Lin, S., Talbot, P., Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLoS One 8 (2013), 1–11, 10.1371/journal.pone.0057987.
195. Winstock, A.R., Vaping Drugs - Tech, Drugs and Profit - the Perfect Storm or Just a Better High?. 2017 Accessed 13 December 2017 https://www.globaldrugsurvey.com/gds2017-launch/vaping-drugs-tech-drugs-and-profit-the-perfect-storm-or-just-a-better-high/.
196. Yu, S., Zhu, L., Shen, Q., Bai, X., Di, X., Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav. Neurol., 2015, 2015, 10.1155/2015/103969.
197. Zawilska, J.B., Andrzejczak, D., Next generation of novel psychoactive substances on the horizon - a complex problem to face. Drug. Alcohol. Depend. 157 (2015), 1–17, 10.1016/j.drugalcdep.2015.09.030.
198. Zhang, Z., Zheng, X., Zeng, D.D., Leischow, S.J., Tracking dabbing using search query surveillance: a case study in the United States. J. Med. Internet Res., 18, 2016, e252, 10.2196/jmir.5802.